Gastroenteropancreatic Neuroendocrine Tumors with Liver Metastases in Korea: A Clinicopathological Analysis of 72 Cases in a Single Institute

다국어 초록 (Multilingual Abstract)

Purpose Management of gastroenteropancreatic (GEP) neuroendocrine tumors with liver metastases(NETLM) presents many clinical challenges. Assessment of the extent of disease and primarytumor site is crucial for management. In this study, we investigated the primary tumor sitesand prognostic factors in GEP NETLM among Korean patients.
Materials and MethodsWe reviewed the medical records of 72 Korean patients diagnosed with GEP NETLMbetween January 1999 and May 2013, focusing on their clinical and pathologic characteristics.
ResultsThe most frequently encountered primary tumor sites were the pancreas (n=25, 35%), stomach(n=8, 11%), gall bladder (n=4, 6%) and rectum (n=3, 4%). Twenty-five patients (35%)had occult primary tumor. Twelve patients (17%) had histological grade G1 tumors, 30patients (42%) had G2 tumors, and 30 patients (42%) had G3 tumors. The mean follow-upperiod after histological confirmation of hepatic metastases was 11.30±2.44 months forG3 tumors, 19.67±4.09 months for G2 tumors, and 30.67±6.51 months for G1 tumors.
Multivariate analyses revealed that an unknown primary tumor site (p=0.001) and higherhistological grade (p < 0.001) were independent prognostic indicators for shorter overallsurvival (OS). Most long-term survivors (OS > 24 months) had received antitumor treatment.
ConclusionThe primary tumor site most frequently associated with GEP NETLM was the pancreas.
Unknown primary tumor and higher histological grade were independent prognostic indicatorsfor shorter OS. Patients identified as being at a risk of shorter OS should be followedup closely.

참고문헌 (Reference)

1 Bosman FT, "WHO classification of tumours of the digestive system. World Health Organization classification of tumours, No. 3" IARC Press 2010

2 Granberg D, "Treatment of liver metastases in patients with neuroendocrine tumors" 2012 : 790635-, 2012

3 Hodul P, "The role of cytoreductive hepatic surgery as an adjunct to the management of metastatic neuroendocrine carcinomas" 13 : 61-71, 2006

4 Kaltsas GA, "The diagnosis and medical management of advanced neuroendocrine tumors" 25 : 458-511, 2004

5 Rindi G, "TNM staging of midgut and hindgut(neuro)endocrine tumors : a consensus proposal including a grading system" 451 : 757-762, 2007

6 Mayo SC, "Surgery versus intra-arterial therapy for neuroendocrine liver metastasis : a multicenter international analysis" 18 : 3657-3665, 2011

7 Printz C, "Racial and ethnic disparities in breast cancer : experts gain new clues about differences in mortality rates among racial groups" 119 : 3739-3741, 2013

8 Rindi G, "Prognostic factors in gastrointestinal endocrine tumors" 18 : 145-149, 2007

9 Yao JC, "One hundred years after"carcinoid" : epidemiology of and prognostic factors for neuroendocrine tumors in 35, 825 cases in the United States" 26 : 3063-3072, 2008

10 Janson ET, "Nordic Guidelines 2010 for diagnosis and treatment of gastroenteropancreatic neuroendocrine tumours" 49 : 740-756, 2010

11 Hauso O, "Neuroendocrine tumor epidemiology : contrasting Norway and North America" 113 : 2655-2664, 2008

12 Frilling A, "Multimodal management of neuroendocrine liver metastases" 12 : 361-379, 2010

13 Panzuto F, "Metastatic and locally advanced pancreatic endocrine carcinomas : analysis of factors associated with disease progression" 29 : 2372-2377, 2011

14 Sutcliffe R, "Management of neuroendocrine liver metastases" 187 : 39-46, 2004

15 Cheung TT, "Long term survival analysis of hepatectomy for neuroendocrine tumour liver metastases" 2014 : 524045-, 2014

16 Salama A, "Ki-67 is a powerful tool for grading neuroendocrine tumors among Egyptian patients : a 10-year experience" 140 : 653-661, 2014

17 Wang SC, "Identification of unknown primary tumors in patients with neuroendocrine liver metastases" 145 : 276-280, 2010

18 Modlin IM, "Gastroenteropancreatic neuroendocrine tumours" 9 : 61-72, 2008

19 Yao JC, "Everolimus for advanced pancreatic neuroendocrine tumors" 364 : 514-523, 2011

20 Pavel M, "ENETS Consensus Guidelines for the management of patients with liver and other distant metastases from neuroendocrine neoplasms of foregut, midgut, hindgut, and unknown primary" 95 : 157-176, 2012

21 조미연, "Current Trends of the Incidence and Pathological Diagnosis of Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs) in Korea 2000-2009: Multicenter Study" 대한암학회 44 (44): 157-165, 2012

22 Rindi G, "Consensus guidelines for the management of patients with digestive neuroendocrine tumors : the second event and some final considerations" 87 : 5-7, 2008

23 Modlin IM, "A 5-decade analysis of 13, 715 carcinoid tumors" 97 : 934-959, 2003